Hire an Advanced Robo-Advisor to Trade BSX on Your Behalf.
- Street Sentiment
- Personalized Strategy
- Free Trading Simulator
Course of Action
Sentiment (10 days)
- Strong Buy
- Strong Sell
DAILY PRICE CHANGE VS SENTIMENT
Why Smart Auto-Trading?
Smart Auto-Trading is an advanced robo-advisor designed to provides investors with a trading partner to automate systematic investing. Its robo is designed to screens, monitors and auto-trades elite stocks like BOSTON SCIENTIFIC CORPORATION (BSX) using artificial intelligence, social media and market data to augments your potential as an investor.
Smart Auto-Trading produces short-term trades which makes it an ideal tool for trading in tax-deferred accounts such as IRA, SIMPLE IRA, Rollover IRA, 529 College Plans, Keoghs and UGMA. If also works in taxable accounts. Just be aware that if you elect to auto-trade using Smart Auto-Trading in a regular brokerage account, you will be taxed at regular income. Make sure you understand your tax situation before using Smart Auto-trading.
Using Smart Auto-Trading is easy. It connects to your brokerage account at Ally Invest, one of the most trusted broker/dealer in the United States. All you need to do is open an account with them, put a minimum of $5,000 in your account and connect Smart Auto-Trading to trade.
There are clear benefits associated with using a robo-advisor such as Smart Auto-Trading to help you reach your financial goals. Smart Auto-Trading simplifies stock investing down to a few steps. It auto-trades for you, using your personalized strategy, while you attend more important life events.
Using Smart Auto-Trading is like having thousands of traders working for you to help you reach your financial goals.
Smart Auto-Trading actively trades which is different from passive investing. The robo is on the lookout working to maximize your potential every business day of the year. It trades on the news taking advantage of price changes and trends by listening into trader's communications and by validating this information with market data.
Smart Auto-Trading is one of the first robo-advisor to take advantage of Government grade listening technology, artificial intelligence, social media and market data natively.
Try Smart Auto-Trading today!
You can test Smart Auto-Trading in simulation mode, risk free, Stock Circles today.
Disclaimer: Past performance may not be indicative of future results. Therefore, you should assume that the future performance of any specific investment, investment strategy (including robo-strategies), or product made in reference directly or indirectly on this website, will be profitable or equal to corresponding indicated performance levels. Robot-Advisors like other investment methods rely on favorable market conditions to provide positive outcomes.
BOSTON SCIENTIFIC CORPORATION (BSX) News
Boston Scientific Corporation (BSX) Earning Somewhat Positive News Coverage, Analysis Shows
Media coverage about Boston Scientific Corporation (NYSE:BSX) has trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Boston Scientific Corporation earned a news impact score of 0.20 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 47.8097611268375 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
BSX has been the topic of several recent research reports. Royal Bank Of Canada raised their target price on shares of Boston Scientific Corporation from $29.00 to $31.00 and gave the company an “outperform” rating in a research note on Friday, June 9th. BidaskClub upgraded Boston Scientific Corporation from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 10th. Wells Fargo & Company reiterated an “outperform” rating and issued a $31.00 price target (up from $29.50) on shares of Boston Scientific Corporation in a research report on Friday, June 16th. BMO Capital Markets reaffirmed a “buy” rating and issued a $30.00 target price on shares of Boston Scientific Corporation in a research note on Wednesday, June 21st. Finally, Needham & Company LLC boosted their price target on shares of Boston Scientific Corporation from $30.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 22nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $30.12.
Shares of Boston Scientific Corporation (NYSE BSX) opened at 29.47 on Tuesday. Boston Scientific Corporation has a one year low of $19.67 and a one year high of $29.47. The stock has a 50 day moving average of $27.99 and a 200-day moving average of $26.89. The company has a market capitalization of $40.44 billion, a PE ratio of 52.72 and a beta of 1.09.
Boston Scientific Corporation (NYSE:BSX) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the prior year, the company posted $0.27 earnings per share. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, equities analysts forecast that Boston Scientific Corporation will post $1.26 earnings per share for the current fiscal year.
In other news, CFO Daniel J. Brennan sold 92,158 shares of the company’s stock in a transaction that occurred on Tuesday, July 11th. The stock was sold at an average price of $27.48, for a total transaction of $2,532,501.84. Following the sale, the chief financial officer now directly owns 235,421 shares of the company’s stock, valued at approximately $6,469,369.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael P. Phalen sold 15,500 shares of the firm’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $28.72, for a total transaction of $445,160.00. The disclosure for this sale can be found here. Insiders have sold 276,318 shares of company stock valued at $7,567,967 in the last quarter. 0.74% of the stock is currently owned by company insiders.Get Started today! - Risk Free